A Phase IIa, randomized, double-blind, placebo-controlled study to evaluate multiple doses of GLPG2222 in subjects with Cystic Fibrosis who are homozygous for the F508del mutation
Latest Information Update: 17 Sep 2021
At a glance
- Drugs Galicaftor (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions
- Acronyms FLAMINGO
- Sponsors Galapagos NV
- 02 Jan 2018 Results presented in a Galapagos NV media release.
- 17 Nov 2017 Status changed from active, no longer recruiting to completed.
- 12 Sep 2017 Status changed from recruiting to active, no longer recruiting.